Abstract:BackgroundsAlzheimer’s disease (AD) is a multifactorial neurodegenerative disease. The treatment of AD through multiple pathological targets may generate therapeutic efficacy better. The multifunctional molecules that simultaneously hit several pathological targets have been of great interest in the intervention of AD.MethodsHere, we combined the chalcone scaffold with carbamate moiety and 5,6-dimethoxy-indanone moiety to generate a novel multi-target-directed ligand (MTDL) molecule (E)-3-((5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)-methyl)phenylethyl(methyl) carbamate (named AP5). In silico approaches were used to virtually predict the binding interaction of AP5 with AChE, the drug-likeness, and BBB penetrance, and later validated by evaluation of pharmacokinetics (PK) in vivo by LC-MS/MS. Moreover, studies were conducted to examine the potential of AP5 for inhibiting AChE and AChE-induced amyloid-β (Aβ) aggregation, attenuating neuroinflammation, and providing neuroprotection in the APP/PS1 model of AD.ResultsWe found that AP5 can simultaneously bind to the peripheral and catalytic sites of AChE by molecular docking. AP5 exhibited desirable pharmacokinetic (PK) characteristics including oral bioavailability (67.2%), >10% brain penetrance, and favorable drug-likeness. AP5 inhibited AChE activity and AChE-induced Aβ aggregation in vivo and in vitro. Further, AP5 lowered Aβ plaque deposition and insoluble Aβ levels in APP/PS1 mice. Moreover, AP5 exerted anti-inflammatory responses by switching microglia to a disease-associated microglia (DAM) phenotype and preventing A1 astrocytes formation. The phagocytic activity of microglial cells to Aβ was recovered upon AP5 treatment. Importantly, chronic AP5 treatment significantly prevented neuronal and synaptic damage and memory deficits in AD mice.ConclusionTogether, our work demonstrated that AP5 inhibited the AChE activity, decreased Aβ plaque deposition by interfering Aβ aggregation and promoting microglial Aβ phagocytosis, and suppressed inflammation, thereby rescuing neuronal and synaptic damage and relieving cognitive decline. Thus, AP5 can be a new promising candidate for the treatment of AD.

A Novel Acetylcholinesterase Inhibitor and Calcium Channel Blocker SCR-1693 Improves Aβ25–35-impaired Mouse Cognitive Function

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Novel Multipotent AChEI-CCB Attenuates Hyperhomocysteinemia-Induced Memory Deficits and Neuropathologies in Rats

Inhibition of Delta-Secretase Improves Cognitive Functions in Mouse Models of Alzheimer’s Disease

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice

A Novel Multifunctional 5,6-Dimethoxy-indanone-chalcone-carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation

Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase

Bis(9)-(−)-Meptazinol, a Novel Dual-Binding AChE Inhibitor, Rescues Cognitive Deficits and Pathological Changes in APP/PS1 Transgenic Mice

Design, synthesis and evaluation of novel scutellarin and scutellarein-N,N-bis-substituted carbamate-l-amino acid derivatives as potential multifunctional therapeutics for Alzheimer’s disease

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease

Development of the “hidden” multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease

Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease

New Multi-Target-directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol.